Y-mAbs Therapeutics, Inc. Common Stock

YMAB XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

390M

Short interest (Sep 15)

2.3%

Net Short (Sep 15 ): 0.0%

Borrow Fee

0.69%

Available Shares

Price Chart

Company Overview

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001722964

Asset Type: CS

Market Data

Market Cap: $391,224,796

Employees: 107

Status: Active

Short Interest

Current Borrow Fee 0.69%

Range: 0.69% - 0.69%

Available Shares 0

Range: 0 - 0

Recent Changes

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime